Taldefgrobep alfa is the only myostatin inhibitor in clinical development that targets both myostatin and activin A signaling, two key regulators of muscle mass and adipose tissue
- RESILIENT, the pivotal clinical trial in spinal muscular atrophy, was designed to test the efficacy and safety of taldefgrobep alfa as adjunctive therapy to increase muscle in SMA patients treated with standard of care nusinersen, risdiplam or onasemnogene abeparvovec-xioi
https://finance.yahoo.com/news/biohaven-completes-enrollment-pivotal-phase-110000712.html
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.